Economic evaluation of direct oral anticoagulants (DOACs) for venous thromboembolism with different etiologies: a systematic review
Authors:
Open Access
- 10 February 2026
- journal article
- review article
- Published by Springer Nature in Health Economics Review
- Vol. 16 (1)
Abstract
Venous thromboembolism (VTE) imposes significant clinical and economic burdens. While direct oral anticoagulants (DOACs) offer favorable efficacy and safetKeywords
This publication has 29 references indexed in Scilit:
- A Cost-Effectiveness Analysis of Rivaroxaban Compared to Warfarin for the Management of Venous Thromboembolism in Western KenyaClinical Drug Investigation, 2025
- Cost-effectiveness of apixaban and rivaroxaban in thromboprophylaxis of cancer patients treated with chemotherapy in SpainJournal of Medical Economics, 2023
- Cost-effectiveness analysis of extended thromboprophylaxis with rivaroxaban versus no prophylaxis in high-risk patients after hospitalisation for COVID-19: an economic modelling studyThe Lancet Regional Health - Americas, 2023
- Cost-Utility Analysis Comparing Direct Oral Anticoagulant and Low Molecular Weight Heparin Therapies for Secondary Prevention of Cancer-Associated ThrombosisClinical Drug Investigation, 2022
- Cost-effectiveness of direct oral anticoagulants compared to low-molecular-weight-heparins for treatment of cancer associated venous thromboembolism in SpainJournal of Medical Economics, 2022
- Thromboprophylaxis of Patients Submitted to Total Hip and Knee Arthroplasty: A Cost-Effectiveness Assessment From the Perspective of the Brazilian National Health SystemValue in Health Regional Issues, 2022
- Cost-effectiveness of apixaban for prevention of venous thromboembolic events in patients after gynecologic cancer surgeryGynecologic Oncology, 2020
- Cost‐effectiveness analysis of low‐dose direct oral anticoagulant (DOAC) for the prevention of cancer‐associated thrombosis in the United StatesCancer, 2020
- Antithrombotic Therapy for VTE DiseaseChest, 2016
- Developing a scoring system to quality assess economic evaluationsThe European Journal of Health Economics, 2002